Research. Advocacy. Support.
Know Your Risks
About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease.
An OCRFA funded study, published on January 13, 2017 in Oncotarget, sheds light on EMSY, a gene that researchers at New York University Langone Medical Center now understand to have a role similar to those of BRCA1 and BRCA2. BRCA1 and BRCA2 are well known genes that, when working, help with DNA damage repair, which… More
Results from the ARIEL2 trial, funded in part by OCRFA’s grant to the Stand Up to Cancer Ovarian Cancer Dream Team, were recently published in The Lancet. The goal of the trial was to test if the efficacy of rucaparib, an oral PARP inhibitor, was dependent on the type of tumor mutation. The international study… More
(January 30, 2017) In a study funded in part by OCRFA, and published this month in Oncotarget, researchers, including first author and former OCRFA grantee Petar Jelinic, PhD, studied EMSY, a putative BRCAness gene, and its role in the suppression of DNA damage repair in ovarian cancer cells. The EMSY gene is amplified in approximately… More
Join us for an evening of laugh-out-loud stand up performances, a raucous live auction, and cocktail...May 15 @ 6:00 pm - 8:30 pm EDT
At the 2016 Ovarian Cancer National Conference, attendees heard from the country’s top researc...July 7 @ 8:00 am - July 9 @ 5:00 pm EDT
OCRFA’s Super Saturday is a daylong shopping event that brings top luxury name brands in high ...July 29 @ 8:00 am - 5:00 pm EDT